Bortezomib This page contains brief information about bortezomib and a collection of links to more information from the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the National Library of Medicine (NLM). US Brand Name(s): | ![](https://webarchive.library.unt.edu/eot2008/20090114151358im_/http://www.cancer.gov/images/spacer.gif) | VELCADE | ![](https://webarchive.library.unt.edu/eot2008/20090114151358im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20090114151358im_/http://www.cancer.gov/images/spacer.gif) | FDA Approved: | ![](https://webarchive.library.unt.edu/eot2008/20090114151358im_/http://www.cancer.gov/images/spacer.gif) | Yes |
Bortezomib is approved by the Food and Drug Administration (FDA) to treat multiple myeloma.
It is also approved to treat mantle cell lymphoma in patients who have already received at least one other type of treatment. Bortezomib is also being studied in the treatment of other types of cancer.
Information from the FDA
Patient Information Sheet on Bortezomib - A lay language summary of important information about this drug that may include the following:
- FDA warnings or alerts about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This FDA patient information sheet applies only to approved uses of the medicine. However, much of the information may also apply to unapproved uses that are being studied.
FDA Approval for Bortezomib - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
Information from the NCIDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Clinical Trial Results: Bortezomib Approved for First-Line Treatment of Multiple Myeloma (09/11/2008) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Drug Combination Shows Benefit in Relapsed/Refractory Multiple Myeloma (08/28/2007) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Bortezomib Delays Progression of Multiple Myeloma Longer than Standard Therapy: Results of the APEX Trial
(06/05/2004) - Important clinical trial results for this drug, background information, and how the trial was done.
Information from the NLM
MedlinePlus Information on Bortezomib - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied. Clinical TrialsClinical Trials for Bortezomib - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.
Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top |